Biocon Biologics Hails ‘Milestone’ Human Insulin Nod
Following EMA CHMP Positive Opinion For Inpremzia Biosimilar In Late February
Biocon Biologics has welcomed the recent “milestone” positive opinion from the EMA’s CHMP for the Inpremzia biosimilar human insulin rival to Actrapid, on which it has partnered with Celerity Pharmaceuticals.
